PebbleAtlas
PEBBLE / ATLAS
Open research access
PRECLINICAL PUBLICATION · 2020

CDX-301: a novel medical countermeasure for hematopoietic acute radiation syndrome in mice.

Mouse / Radiation

Evidence by therapy association

Study details and outcomes are extracted in the context of a specific intervention. Separate associations are retained rather than silently merged.

PMID 32019942 ↗2020Reported benefit

CDX-301: a novel medical countermeasure for hematopoietic acute radiation syndrome in mice.

MouseRadiationCD2F1Malen = Groups of 24 mice for survival studies; 16 mice per group f…Subcutaneous, at the nape of the neck400, 800, 1600 or 2000 ug/kg in 0.1 mL; 14-day acute safety…Prophylaxis at 12, 24, 48 or 72 h before total body irradiation; mitigation at…

Model: Cobalt-60 gamma total body irradiation producing haematopoietic acute radiation syndrome; doses used included 7 Gy (myelosuppression), 9.25 Gy (LD70/30) and 8.0 to 10.5 Gy for dose reduction factor studies

A single subcutaneous dose of CDX-301 given from 24 h before to 24 h after total body irradiation significantly improved 30-day survival. Survival was not dose-dependent; 12 h and 24 h pre-irradiation dosing gave 100% survival, and 1600 ug/kg given 4 h after 9.25 Gy raised survival to 54% versus 22…

Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.